TRAP
MCID: TRD008
MIFTS: 34

Triiodothyronine Receptor Auxiliary Protein (TRAP)

Aliases & Classifications for Triiodothyronine Receptor Auxiliary Protein

MalaCards integrated aliases for Triiodothyronine Receptor Auxiliary Protein:

Name: Triiodothyronine Receptor Auxiliary Protein 56
Trap 56

External Ids:

OMIM 56 190445

Summaries for Triiodothyronine Receptor Auxiliary Protein

MalaCards based summary : Triiodothyronine Receptor Auxiliary Protein, also known as trap, is related to periodic fever, familial, autosomal dominant and thyroid dyshormonogenesis 1. An important gene associated with Triiodothyronine Receptor Auxiliary Protein is TRAP (Triiodothyronine Receptor Auxiliary Protein). The drugs Certoparin and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and eye.

More information from OMIM: 190445

Related Diseases for Triiodothyronine Receptor Auxiliary Protein

Diseases related to Triiodothyronine Receptor Auxiliary Protein via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1221)
# Related Disease Score Top Affiliating Genes
1 periodic fever, familial, autosomal dominant 12.4
2 thyroid dyshormonogenesis 1 11.7
3 neural tube defects 11.4
4 coronary artery dissection, spontaneous 11.4
5 hidradenitis suppurativa 11.4
6 nerve compression syndrome 11.4
7 gas gangrene 11.4
8 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.3
9 spondyloenchondrodysplasia with immune dysregulation 11.3
10 epidermoid brain cyst 11.3
11 duodenal atresia 11.1
12 hepatic fibrosis, severe due to schistosoma mansoni infection 11.1
13 dehydrated hereditary stomatocytosis 2 11.1
14 tonsillitis 11.1
15 fox-fordyce disease 11.1
16 miliaria 11.1
17 paraphimosis 11.1
18 priapism 11.1
19 catamenial pneumothorax 11.1
20 autoimmune disease 10.4
21 aneurysm 10.4
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
23 vasculitis 10.4
24 systemic lupus erythematosus 10.3
25 lung disease 10.3
26 west nile virus 10.3
27 hair whorl 10.3
28 lupus erythematosus 10.3
29 malaria 10.2
30 helix syndrome 10.2
31 hydrocephalus 10.2
32 amyloidosis 10.2
33 cystic fibrosis 10.2
34 pulmonary disease, chronic obstructive 10.2
35 kala-azar 1 10.2
36 leishmaniasis 10.2
37 pulmonary embolism 10.2
38 anca-associated vasculitis 10.2
39 chikungunya 10.2
40 thrombosis 10.2
41 patent foramen ovale 10.2
42 thrombophilia due to thrombin defect 10.2
43 encephalitis 10.2
44 rapidly involuting congenital hemangioma 10.2
45 pica disease 10.2
46 exanthem 10.1
47 vaccinia 10.1
48 periodontitis 10.1
49 bone resorption disease 10.1
50 macular degeneration, age-related, 1 10.1

Graphical network of the top 20 diseases related to Triiodothyronine Receptor Auxiliary Protein:



Diseases related to Triiodothyronine Receptor Auxiliary Protein

Symptoms & Phenotypes for Triiodothyronine Receptor Auxiliary Protein

Clinical features from OMIM:

190445

Drugs & Therapeutics for Triiodothyronine Receptor Auxiliary Protein

Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 266)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Certoparin Approved, Investigational Phase 4
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
4
Verteporfin Approved, Investigational Phase 4 129497-78-5
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Ranibizumab Approved Phase 4 347396-82-1 459903
7
Thrombin Approved, Investigational Phase 4
8
Vorapaxar Approved Phase 4 618385-01-6
9
Sucralfate Approved Phase 4 54182-58-0
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
14 Anticoagulants Phase 4
15 Dipeptidyl-Peptidase IV Inhibitors Phase 4
16 Incretins Phase 4
17 Immunologic Factors Phase 4
18 Photosensitizing Agents Phase 4
19 Citrate Phase 4
20 Gastrointestinal Agents Phase 4
21 Antacids Phase 4
22 Anti-Ulcer Agents Phase 4
23 Ranitidine bismuth citrate Phase 4
24 Histamine H2 Antagonists Phase 4
25 Bismuth tripotassium dicitrate Phase 4
26
Bismuth Phase 4 7440-69-9 16682734 105143
27 Pharmaceutical Solutions Phase 4
28 Calcium, Dietary Phase 4
29 Hormones Phase 4
30 Micronutrients Phase 4
31 Vitamins Phase 4
32 Trace Elements Phase 4
33 Nutrients Phase 4
34 Calciferol Phase 4
35 Anesthetics Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
tannic acid Approved Phase 3 1401-55-4
38
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
39
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
40
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
41
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
42
Warfarin Approved Phase 2, Phase 3 81-81-2 6691 54678486
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
45 Grape Approved Phase 2, Phase 3
46
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
47
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
48
Sofosbuvir Approved Phase 3 1190307-88-0 45375808
49
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
50
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 335)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
3 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
4 AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study) Completed NCT01543568 Phase 4 aflibercept 2.0 mg
5 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
6 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
7 A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy Completed NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
8 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
9 Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES) Completed NCT02581891 Phase 4 Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321);Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
10 A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration Completed NCT02305238 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
11 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
12 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
13 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
14 Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study Completed NCT02875028 Phase 4 Vorapaxar;Placebo
15 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
16 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
17 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
18 Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
19 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Recruiting NCT02621645 Phase 4
20 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
21 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Active, not recruiting NCT02999204 Phase 4 Vitamin D3
22 The Effect of the Tunneling Technique With Subepithelial Connective Tissue Graft Versus Tunneling Technique With Deepithelialized Free Gingival Graft on the Papillary Height in the Treatment of RT2 Recession Defect: a Randomized Clinical Trial. Not yet recruiting NCT04104087 Phase 4
23 Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY Suspended NCT02863744 Phase 4
24 Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax Unknown status NCT00154895 Phase 3 intrapleural minocycline instillation
25 Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial Unknown status NCT00720967 Phase 3
26 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
27 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
28 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
29 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
30 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
31 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
32 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
33 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
34 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
35 An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME) Completed NCT02818998 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
36 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
37 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
38 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
39 Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema Completed NCT02772497 Phase 2, Phase 3 Ziv aflibercept
40 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) Completed NCT00129545 Phase 2, Phase 3 Warfarin
41 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
42 Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial ("VITDAL@ICU") Completed NCT01130181 Phase 3 Cholecalciferol;Placebo
43 A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed NCT00532155 Phase 3 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;Docetaxel (Taxotere®);Dexamethasone (pre- and post-medication for docetaxel)
44 Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia Completed NCT00713167 Phase 2, Phase 3 Grape Seed Extract (Vitagrape);Placebo of Grape Seed Extract
45 Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet activation-a Single Center Pilot Study Completed NCT03455218 Phase 2, Phase 3 Nitric Oxide;Placebo
46 A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen Completed NCT00561470 Phase 3 Placebo;Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin);FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
47 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
48 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
49 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
50 Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods Completed NCT00495963 Phase 3

Search NIH Clinical Center for Triiodothyronine Receptor Auxiliary Protein

Genetic Tests for Triiodothyronine Receptor Auxiliary Protein

Anatomical Context for Triiodothyronine Receptor Auxiliary Protein

MalaCards organs/tissues related to Triiodothyronine Receptor Auxiliary Protein:

40
Bone, Neutrophil, Eye, Endothelial, Testes, Liver, Lung

Publications for Triiodothyronine Receptor Auxiliary Protein

Articles related to Triiodothyronine Receptor Auxiliary Protein:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
3,5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. 56 61
1708100 1991
2
TRAM1 protein may support ER protein import by modulating the phospholipid bilayer near the lateral gate of the Sec61-channel. 61
32013668 2020
3
Coagulation monitoring and transfusion in major non-emergency orthopaedic surgery - An observational study. 61
32280164 2020
4
Microplastics in bloom-forming macroalgae: Distribution, characteristics and impacts. 61
32361243 2020
5
Low frequency magnetic field plus high pH promote the quality of pork myofibrillar protein gel: A novel study combined with low field NMR and Raman spectroscopy. 61
32416422 2020
6
Rapid and on-site detection of multiple fentanyl compounds by dual-ion trap miniature mass spectrometry system. 61
32498861 2020
7
Targeted analysis of ceramides and cerebrosides in yellow lupin seeds by reversed-phase liquid chromatography coupled to electrospray ionization and multistage mass spectrometry. 61
32344348 2020
8
Thermal- and collision-induced dissociation studies of functionalized imidazolium-based ionic liquid cations. 61
32578308 2020
9
HPLC-MS/MS-based targeted metabolomic method for profiling of malvidin derivatives in dry red wines. 61
32517914 2020
10
Sorption of G-agent simulant vapours on human scalp hair. 61
32413347 2020
11
Diaporisoindole E inhibits RANKL-induced osteoclastogenesis via suppression of PI3K/AKT and MAPK signal pathways. 61
32510335 2020
12
Baicalin inhibits root resorption during tooth movement in a rodent model. 61
32470833 2020
13
Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium. 61
32513536 2020
14
The RNA-binding protein Cpeb4 is a novel positive regulator of osteoclast differentiation. 61
32517870 2020
15
Does communicable diseases (including COVID-19) may increase global poverty risk? A cloud on the horizon. 61
32422482 2020
16
Selective serotonin reuptake inhibitors (SSRI) affect murine bone lineage cells. 61
32450170 2020
17
High-energy x-ray radiation effects on the exfoliated quasi-two-dimensional β-Ga2O3 nanoflake field-effect transistors. 61
32396888 2020
18
GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo. 61
32485573 2020
19
Dolichosin A, a coumestan isolated from Glycine tabacina, inhibits IL-1β-induced inflammation in SW982 human synovial cells and suppresses RANKL-induced osteoclastogenesis: From network pharmacology to experimental pharmacology. 61
32376366 2020
20
Three-Layer Sulfur Cathode with a Conductive Material-Free Middle Layer. 61
32126679 2020
21
Polymeric monolithic microcartridges with gold nanoparticles for the analysis of protein biomarkers by on-line solid-phase extraction capillary electrophoresis-mass spectrometry. 61
32381302 2020
22
Bacterial intracellularly active toxins: Membrane localisation of the active domain. 61
32353188 2020
23
On-line microplasma decomposition of gaseous phase interference for solid sampling mercury analysis in aquatic food samples. 61
32493588 2020
24
The effect of molecular structure of polyphenols on the kinetics of the trapping reactions with methylglyoxal. 61
32146288 2020
25
A high-throughput method for dereplication and assessment of metabolite distribution in Salvia species using LC-MS/MS. 61
32211205 2020
26
Quantitation of spin probe-detectable oxidants in cells using electron paramagnetic resonance spectroscopy: To probe or to trap? 61
32376456 2020
27
Removal of Circulating Neutrophil Extracellular Trap Components With an Immobilized Polymyxin B Filter: A Preliminary Study. 61
31764624 2020
28
A needle trap device method for sampling and analysis of semi-volatile organic compounds in air. 61
32234620 2020
29
Heterogeneity of fibroblasts from radicular cyst influenced osteoclastogenesis and bone destruction. 61
32112663 2020
30
Immune serum-activated human macrophages coordinate with eosinophils to immobilize Ascaris suum larvae. 61
32394439 2020
31
A natural compound (LCA) isolated from Litsea cubeba inhibits RANKL-induced osteoclast differentiation by suppressing Akt and MAPK pathways in mouse bone marrow macrophages. 61
32298753 2020
32
Dynamic microstructural changes in alveolar bone in ligature-induced experimental periodontitis. 61
31713702 2020
33
Sodium-induced inflammation-an invisible player in resistant hypertension. 61
32203452 2020
34
Biofilm and planktonic microbial communities in highly acidic soil (pH < 3) in the Soos National Nature Reserve, Czech Republic. 61
32449144 2020
35
A sensitive and accurate analytical method for the determination of cadmium in food samples: Molybdenum coated T-shape slotted quartz tube flame atomic absorption spectrophotometry. 61
32163838 2020
36
Implementation of Synaptic Device Using Various High-k Gate Dielectric Stacks. 61
31968460 2020
37
Resonance Raman spectroscopic studies of peroxo and hydroperoxo intermediates in lauric acid (LA)-bound cytochrome P450 119. 61
32470906 2020
38
Osteogenic in vitro training of bone marrow mesenquimal cells for application in segmentary bone resections. 61
32473814 2020
39
The emergence of picokelvin physics. 61
32303019 2020
40
Close relationship between the state of the oxygen evolving complex and rice cold stress tolerance. 61
32540008 2020
41
A trade-off between adsorption and photocatalysis over ZIF-derived composite. 61
32197202 2020
42
In-situ treatment of herbicide-contaminated groundwater-Feasibility study for the cases atrazine and bromacil using two novel nanoremediation-type materials. 61
32208331 2020
43
A critical review on plant biomonitors for determination of polycyclic aromatic hydrocarbons (PAHs) in air through solvent extraction techniques. 61
32443242 2020
44
Effects of carbon nanotubes on the toxicities of copper, cadmium and zinc toward the freshwater microalgae Scenedesmus obliquus. 61
32450458 2020
45
Release of harmful volatile organic compounds (VOCs) from photo-degraded plastic debris: A neglected source of environmental pollution. 61
32302919 2020
46
Synthesis and biological activities of drugs for the treatment of osteoporosis. 61
32335412 2020
47
Alterations in osteocyte mediated osteoclastogenesis during estrogen deficiency and under ROCK-II inhibition: An in vitro study using a novel postmenopausal multicellular niche model. 61
32330507 2020
48
Molecular detection of a novel cyprinid herpesvirus in roach (Rutilus rutilus) and asp (Leuciscus aspius) showing typical signs of carp pox disease. 61
32358627 2020
49
Tea extract increases cell fusion via regulation of cell surface DC-STAMP. 61
32420461 2020
50
Ion trap MS using high trapping gas pressure enables unequivocal structural analysis of three isobaric compounds in a mixture by using energy-resolved mass spectrometry and the survival yield technique. 61
31834966 2020

Variations for Triiodothyronine Receptor Auxiliary Protein

Expression for Triiodothyronine Receptor Auxiliary Protein

Search GEO for disease gene expression data for Triiodothyronine Receptor Auxiliary Protein.

Pathways for Triiodothyronine Receptor Auxiliary Protein

GO Terms for Triiodothyronine Receptor Auxiliary Protein

Sources for Triiodothyronine Receptor Auxiliary Protein

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....